General-purpose panel surveys dealing with older adults can include questions on dependency.
The Clinical Proteomics Programs established for this purpose will design panels of candidate proteins for disease areas, develop high throughput analytic methods, assess the predictive value of these proteomic measurements using biological specimens and clinical data from existing study populations, and establish procedures and standards for quality control.
We hypothesized that the 52 SNP panel would perform in a comparable way to the 19 SNP panel for identification but would be unlikely to match the performance of the 93 SNP AIM panel for assignment of ancestry since this was not the primary purpose of the 52 SNP panel in the first place.
The purpose, that panel said, should be to determine "whether and to what extent personnel at all levels should be held accountable" for any mistakes that contributed to the failure to disrupt the attacks.
For this purpose, a panel of genomic DNA samples including six Cryptosporidium species (C. parvum, C. bovis, C. ryanae, C. andersoni, C. ubiquitum, and C. hominis) and 18 C. parvum GP60 subtypes belonging to the subtype families IIa and IId was used.
For that purpose, a panel of 8 specialists in psychiatric disorders was selected.
For this purpose a panel of biomarkers is most informative, especially when biomarkers for alveolar types I and II cell injury are incorporated.
For this purpose, a panel of cell lines that represent both types of LC was used, displaying different radiosensitivity as measured by surviving cell fraction at 2 Gy (SF2) in clonogenic assays.
For that purpose, the panel recommendations are made available to practising physicians via an online tool that allows a quick 'second opinion' on the appropriateness of treatment for any given patient.
For a similar purpose, this panel also includes event/relationship fields such as primitive associations (e.g., Is-A, Part-Of) as well as common interest ones (e.g., Cause, Binding, Up-regulation, Down-regulation, Expression).
In the determination of HER2 status for treatment purposes, the Panel did not believe that polysomy of chromosome 17, or heterogeneity of expression of HER2 need to be considered.
